Shutting down cancer with Gleevec, Brian Druker

Interviewee: Brian Druker. Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Shutting down cancer)

If you look back at the history of cancer research, in many respects for 30 or 40 years we've been stumbling around in the dark. We understood that cancer is probably a genetic disease but what those genetic abnormalities are that caused the uncontrolled growth of cancer in most cases remain elusive. With Gleevec we've shown that if you understand what drives the growth of a cancer you can shut it down specifically.

chronic myeloid leukemia,causes of cancer,gleevec,location applications,genetic abnormalities,dnai,cancer research,uncontrolled growth,genetic disease,cml,interviewee,leukemia,brian druker,genes,respects,medicine

Related Content

15057. Before and after Gleevec, Brian Druker

Brian Druker talks about the drug he developed as a turning point in the war on cancer.

  • ID: 15057
  • Source: DNAi

15055. Using DNA science to control CML, Brian Druker

Brian Druker talks about how the drug he designed targets the molecular cause of CML.

  • ID: 15055
  • Source: DNAi

15054. Restoring hope with Gleevec, Brian Druker

Brian Druker talks about how Gleevec has restored patients' hope for the future.

  • ID: 15054
  • Source: DNAi

15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration

View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.

  • ID: 15525
  • Source: DNAi

15056. Approval for Gleevec in record time, Brian Druker

Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.

  • ID: 15056
  • Source: DNAi

15042. The first day of clinical trials for Gleevec, Bud and Yvonne

Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.

  • ID: 15042
  • Source: DNAi

15041. Getting the diagnosis of chronic myeloid leukemia, Bud

Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.

  • ID: 15041
  • Source: DNAi

1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1

Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.

  • ID: 1013
  • Source: IC

15706. Philadelphia chromosome

A mutation that gives rise to the Philadelphia chromosome gives rise to leukemia.

  • ID: 15706
  • Source: DNAi

15994. The chronic myeloid leukemia (CML) mutation

View the animation to learn about the Philadelphia chromosome, the abnormal chromosome that causes chronic myeloid leukemia.

  • ID: 15994
  • Source: DNAi